NovaBridge Biosciences (NBP) Asset Utilization Ratio (2022 - 2023)
NovaBridge Biosciences (NBP) posted quarterly Asset Utilization Ratio of 0.01 for Q2 2023, down 14.36% quarter-over-quarter from 0.01 in Q4 2022.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Asset Utilization Ratio (2022 - 2023) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Asset Utilization Ratio for 2 consecutive years, with 0.01 the latest figure, recorded in Q2 2023.
- In Q2 2023, Asset Utilization Ratio changed N/A year-over-year to 0.01; the TTM figure through Jun 2023 stood at 0.01 (changed N/A YoY), while the FY2023 annual figure was 0.0, down 37.19% from the prior year.
- Asset Utilization Ratio retreated to 0.01 in Q2 2023 per NBP's latest filing, from 0.01 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.01 in Q4 2022 and bottomed at 0.01 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 0.20 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 0.69 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 0.90 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.13 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.54 |
| 10 | NovaBridge Biosciences | 197.68 Mn | 197.68 Mn | - | - |